Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)

No standard options existed for human epidermal growth factor receptor 2 (HER2)‐positive advanced breast cancer that progresses after second‐line trastuzumab emtansine therapy before 2020. The purpose of this study was to examine the efficacy of pertuzumab retreatment after disease progression follo...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Yutaka, Iwata, Hiroji, Taira, Naruto, Masuda, Norikazu, Takahashi, Masato, Yoshinami, Tetsuhiro, Ueno, Takayuki, Toyama, Tatsuya, Yamanaka, Takashi, Takano, Toshimi, Kashiwaba, Masahiro, Tsugawa, Koichiro, Hasegawa, Yoshie, Tamura, Kenji, Tada, Hiroshi, Hara, Fumikata, Fujisawa, Tomomi, Niikura, Naoki, Saji, Shigehira, Morita, Satoshi, Toi, Masakazu, Ohno, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459345/
https://www.ncbi.nlm.nih.gov/pubmed/35754298
http://dx.doi.org/10.1111/cas.15474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459345/
https://www.ncbi.nlm.nih.gov/pubmed/35754298
http://dx.doi.org/10.1111/cas.15474

Ejemplares similares